Edition:
India

Pharming Group NV (PHAR.AS)

PHAR.AS on Amsterdam Stock Exchange

1.50EUR
19 Jan 2018
Change (% chg)

€0.19 (+14.24%)
Prev Close
€1.31
Open
€1.31
Day's High
€1.50
Day's Low
€1.30
Volume
56,014,099
Avg. Vol
34,138,007
52-wk High
€1.50
52-wk Low
€0.25

Select another date:

Wed, Jan 17 2018

BRIEF-Pharming Announces FDA Acceptance For Review Of Supplemental Biologics License Application

* PHARMING ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Announces Further Conversion Of Ordinary Convertible Bonds

* BONDHOLDERS CONVERT €7.7 MILLION OF THEIR REMAINING BONDS INTO PHARMING SHARES AND CASH

BRIEF-Pharming Group Announces Significant Conversion Of Its Ordinary Convertible Bonds

* PHARMING ANNOUNCES SIGNIFICANT CONVERSION OF ITS ORDINARY CONVERTIBLE BONDS

BRIEF-Pharming Submits License Application to FDA for Ruconest

* PHARMING SUBMITS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION TO FDA FOR RUCONEST® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA ATTACKS

BRIEF-Pharming Group Q3 net result swings to profit of 7.5 million euros from Q2

* ‍Q3 NET RESULT IMPROVED TO EUR 7.5 MILLION LOSS COMPARED WITH A LOSS OF EUR 24.5 MILLION IN Q2​

BRIEF-Pharming Group announces positive data from paediatric clinical trial of Ruconest

* PHARMING ANNOUNCES POSITIVE DATA FROM PAEDIATRIC CLINICAL TRIAL WITH RUCONEST®

BRIEF-Pharming Group partners with Inceptua Medicines Access

* PHARMING GROUP N.V. AND HAEI INTERNATIONAL PATIENT ORGANIZATION ANNOUNCE PARTNERSHIP WITH INCEPTUA MEDICINES ACCESS FOR "HAEI GLOBAL ACCESS PROGRAM"

BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest

* PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE

BRIEF-Pharming Group announces cashless warrant exercises and conversions of its ordinary bonds into shares

* ANNOUNCES CASHLESS WARRANT EXERCISES AND CONVERSIONS OF ITS ORDINARY BONDS INTO SHARES

BRIEF-Pharming Group H1 net loss widens to 30.2 million euros

* SAID ON THURSDAY THAT REVENUES FROM PRODUCT SALES FOR THE HALF YEAR INCREASED BY 617 PCT TO EUR 30.1 MILLION (HY 2016: EUR 4.2 MILLION)

Select another date: